Alena Sorokac Kubolkova, Gabriel Varga, Miroslava Benovska, Lenka Kovacova, Michal Fedorko
{"title":"The role of Fetuin-A and Leucine-rich α-2-glycoprotein in the diagnosis of prostate cancer - a pilot study.","authors":"Alena Sorokac Kubolkova, Gabriel Varga, Miroslava Benovska, Lenka Kovacova, Michal Fedorko","doi":"10.5507/bp.2024.028","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PC) is one of the most frequently diagnosed non-skin solid cancers and is a leading cause of cancer-related death and the incidence increasing. Early diagnosis of the disease improves the outcomes. There is an urgent need for new biomarkers with greater discriminative precision for diagnosis, risk-stratification and treatment. The aim of our study was to evaluate the diagnostic and prognostic potential of Fetuin-A and LRG1 in patients with PC.</p><p><strong>Methods: </strong>Serum levels of Fetuin-A and LRG1 were compared in patients with PC (n=46), a control group 1 including young, healthy subjects (n=26) and control group 2 including patients with negative prostate biopsy (n=46). In PC patients, the levels of both biomarkers were compared in subgroups with different tumour characteristics.</p><p><strong>Results: </strong>We demonstrated a statistically significant higher concentrations of Fetuin-A in PC patients compared to control group 2 (439 mg/L vs. 372 mg/L), P<0.001. No statistically significant difference was found between PC patients and control group 1, nor for LRG1 levels between the three groups. In PC patients, higher serum levels of LRG1 were found in M1 patients compared to M0 (98 mg/L vs. 42 mg/L), P=0.059.</p><p><strong>Conclusion: </strong>Fetuin-A levels are significantly higher in patients with prostate cancer than in patients without malignancy but LRG1 levels do not differ between patients with PC and controls.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Papers-Olomouc","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5507/bp.2024.028","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Prostate cancer (PC) is one of the most frequently diagnosed non-skin solid cancers and is a leading cause of cancer-related death and the incidence increasing. Early diagnosis of the disease improves the outcomes. There is an urgent need for new biomarkers with greater discriminative precision for diagnosis, risk-stratification and treatment. The aim of our study was to evaluate the diagnostic and prognostic potential of Fetuin-A and LRG1 in patients with PC.
Methods: Serum levels of Fetuin-A and LRG1 were compared in patients with PC (n=46), a control group 1 including young, healthy subjects (n=26) and control group 2 including patients with negative prostate biopsy (n=46). In PC patients, the levels of both biomarkers were compared in subgroups with different tumour characteristics.
Results: We demonstrated a statistically significant higher concentrations of Fetuin-A in PC patients compared to control group 2 (439 mg/L vs. 372 mg/L), P<0.001. No statistically significant difference was found between PC patients and control group 1, nor for LRG1 levels between the three groups. In PC patients, higher serum levels of LRG1 were found in M1 patients compared to M0 (98 mg/L vs. 42 mg/L), P=0.059.
Conclusion: Fetuin-A levels are significantly higher in patients with prostate cancer than in patients without malignancy but LRG1 levels do not differ between patients with PC and controls.
背景：前列腺癌（PC）是最常见的非皮肤实体癌之一，也是癌症相关死亡的主要原因之一，而且发病率还在不断上升。疾病的早期诊断可改善预后。目前急需新的生物标志物来提高诊断、风险分级和治疗的精确度。我们的研究旨在评估 Fetuin-A 和 LRG1 在 PC 患者中的诊断和预后潜力：方法：比较了PC患者（46人）、对照组1（包括年轻健康人）（26人）和对照组2（包括前列腺活检阴性患者）（46人）血清中Fetuin-A和LRG1的水平。在 PC 患者中，这两种生物标志物的水平在具有不同肿瘤特征的亚组中进行了比较：结果：与对照组 2 相比，我们发现 PC 患者的 Fetuin-A 浓度明显更高（439 mg/L vs. 372 mg/L）：前列腺癌患者的Fetuin-A水平明显高于非恶性肿瘤患者，但PC患者和对照组的LRG1水平没有差异。
期刊介绍：
Biomedical Papers is a journal of Palacký University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Czech Republic. It includes reviews and original articles reporting on basic and clinical research in medicine.
Biomedical Papers is published as one volume per year in four issues.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
